The present study will assess whether the beneficial effects of a market moderate-alcohol drinking in the form of white wine in humans could be derived from the endogenous formation of hydroxytyrosol (also known DOPET), a potent dietary anti-inflammatory and antioxidant molecule.
Epidemiological studies support that light to moderate alcohol drinking (10-20g per day), may reduce the risk of cardiovascular disease (CVD), stroke, dementia, depression, and all-cause mortality. In addition, moderate red wine consumption has recently shown to be inversely associated with a decline in global cognitive function and the domains of memory and flexibility. The claimed beneficial effects of the Mediterranean diet include prevention of several age-related dysfunctions including cardiovascular and neurodegenerative diseases. These effects have been related to the protection against cognitive decline associated with aging and disease by a number of polyphenols found in red wine and virgin olive oil. Neurodegenerative diseases, as all chronic degenerative diseases, are linked to inflammation and its inter-twined phenomena: the oxidation and the oxidative damage. The interrelationship among chronic degenerative diseases is also evidenced by the fact that vascular (cardiovascular) risk factors are associated to cognitive decline, and these vascular factors are currently the only known modifiable risk factors for Alzheimer disease. There is evidence suggesting that DOPET, also known as hydroxytyrosol (HOTYR), has a role in the cardioprotective and neuroprotective properties of wine. It is a phenolic compound present in virgin olive oil and wine, and it is a potent dietary anti-inflammatory and antioxidant molecule. Biological effects of HOTYR may explain in part some of the beneficial effects for human health that have been credited to moderate ethanol intake (in form of wine). The present project is not intended to provide support for the clinical use of moderate- dose alcohol as a treatment modality for CVD risk patients. Nevertheless, it will investigate a novel mechanism of action that may explain in part beneficial health effects associated to moderate alcohol consumption. This novel mechanism of action is mediated by compounds that at mid/long-term run are susceptible of a pharmaceutical and/or nutraceutical food development.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
33
A dietary beverage: a market white wine, 13º alcohol
tyrosol in capsules
IMIM (Hospital del Mar Medical Research Institute)
Barcelona, Spain
Metabolic: changes in hydroxytyrosol generation
Hydroxytyrosol generation from tyrosol ingestion in urine (24 hours urine collection)
Time frame: change from baseline at 4 weeks
Vascular effects: changes in endothelial function
It will be measured in the morning by monitoring endothelium-mediated changes in the digital pulse waveform, known as the Peripheral Arterial Tone (PAT) signal.
Time frame: change from baseline at 4 weeks
Metabolic effects (n=12)
Additionally, 12 participants will be asked to collect a 24-hour urine specimen at two intervals (0-8 h and 8-24 h) the first day of each intervention, following the treatment ingestion (n=12).
Time frame: up to 24 hours
changes in glucose profile
Glucose will be determined by enzymatic methods (PENTRA 400).
Time frame: change from baseline at 4 weeks
changes in lipid profile
total-cholesterol will be determined by enzymatic methods (PENTRA 400).
Time frame: change from baseline at 4 weeks
changes in lipid profile
HDL-cholesterol will be determined by enzymatic methods (PENTRA 400).
Time frame: change from baseline at 4 weeks
changes in lipid profile
Triglycerides will be determined by enzymatic methods (PENTRA 400).
Time frame: change from baseline at 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
changes in lipid profile
LDL-cholesterol concentrations will be calculated with the Friedewald equation.
Time frame: change from baseline at 4 weeks
changes in oxidation profile
plasma oxidized LDL in urine will be measured by ELISA methods.
Time frame: change from baseline at 4 weeks
changes in inflammation enzymes
High sensitivity C-reactive protein (CRP) (immunoturbidimetry) in plasma by high sensitivity enzyme-immunoassays (ELISAs)
Time frame: change from baseline at 4 weeks
change in endothelial function
Nitric oxide (NO) plasma concentrations will be measured through nitrates/nitrites ratio by colorimetry and those of Endothelin-1 by ELISA (both techniques from Cayman Chem. Co., Ann Arbor, USA).
Time frame: change from baseline endothelial function at 4 weeks
Alcohol biomarker
Ethyl glucuronide in urine by Thermo Scientific Ethyl Glucuronide Enzyme Immunoassay.
Time frame: change from baseline at 4 weeks
Gene expression
Microfluidic cards (TaqMan® Gene Expression Array Microfluidic Card, 32.1 format, Applied Biosystems), 30 genes related with endothelial function and inflammation of a sub-sample of 30 subjects (15 by gender) will be determined in peripheral blood mononucleated cell (PBMC).
Time frame: change from baseline at 4 weeks